

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number
WO 03/089656 A1

(51) International Patent Classification: C12Q 1/00,
G01R 33/465, G01N 24/08

(21) International Application Number: PCT/NO03/00125

(22) International Filing Date: 15 April 2003 (15.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20021886 19 April 2002 (19.04.2002) NO
20023357 11 July 2002 (11.07.2002) NO

(71) Applicants (for all designated States except US): AMER-
SHAM HEALTH AS [NO/NO]; Intellectual Property
Dept., Nycoveien 1-2, P.O. Box 4220 Nydalen, N-0401
Oslo (NO). ARDENKJER-LARSEN, Jan-Henrik
[DK/DK]; Amersham Health R & D AB, P.A. Hanssons
v. 41, S-205 12 Malmö (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CLARKE, Bill
[US/GB]; Amersham plc., The Grove Centre, White Lion
Road, Amersham, Buckinghamshire HP7 9LL (GB).
GOLMAN, Klaes [DK/DK]; Amersham Health R &
D AB, P.A. Hanssons v. 41, S-205 12 Malmö (SE).
LERCHE, Mathilde, H. [DK/DK]; Amersham Health
R & D AB, P.A. Hanssons v. 41, S-205 12 Malmö (SE).
LOOKER, Mike [GB/GB]; Amersham Biosciences, The
Maynard Centre, MC05/K RP2, Cardiff, South Wales
CF14 7YT (GB). O'SULLIVAN, Mike [GB/GB]; Amer-
sham Biosciences, The Maynard Centre, MC03 CD4,
Cardiff, South Wales CF14 7YT (GB). SANTOS, Albie
[GB/GB]; Amersham Biosciences, The Maynard Centre,

MC05/K RP2, Cardiff, South Wales CF14 7YT (GB).
SERVIN, Rolf [SE/SE]; Amersham Health R & D AB,
P.A. Hanssons v. 41, S-205 12 Malmö (SE). THANING,
Mikkel [SE/SE]; Amersham Health R & D AB, P.A.
Hanssons v. 41, S-205 12 Malmö (SE).

(74) Agents: FLECHSLER, Insa et al.; Amersham Health
AS, Nycoveien 1-2, P.O. Box 4220 Nydalen, N-0401 Oslo
(NO).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOUND MIXTURES FOR DETERMINING PROTEIN ACTIVITY USING NMR SPECTROSCOPY

(57) Abstract: The invention relates to methods for determining protein activity using NMR spectroscopy. The present invention provides a method for determining protein activity *in vivo* using probe compounds and enhancing the nuclear polarisation of NMR active nuclei present in the probe compounds (hereinafter termed "hyperpolarisation") prior to NMR analysis. The invention also provides mixtures of probe compounds for the above-mentioned method.

WO 03/089656 A1

METHODS AND COMPOUND MIXTURES FOR DETERMINING PROTEIN ACTIVITY USING NMR SPECTROSCOPY

- The invention relates to methods for determining protein activity using NMR spectroscopy. The present invention provides a method for determining protein activity *in vivo* using probe compounds and enhancing the nuclear polarisation of NMR active nuclei present in the probe compounds (hereinafter termed "hyperpolarisation") prior to NMR analysis. The invention also provides mixtures of probe compounds for the above-mentioned method.
- 10 The ability of an organism to absorb a drug, translocate it, break it down (metabolise it) and finally remove it from the organism itself is crucial to how well a drug will operate in a particular organism or individual. For clinical trialing of a new drug as well as for the therapeutic efficacy of a drug it is important to gain better understanding of the performance of a drug in a human individual or human
- 15 population. Thus, an attempt was made to classify populations into groups of individuals with similar biological characteristics and behaviours. This attempt has become known as phenotyping. In the context of the present invention, a phenotype is defined in one of the three distinct ways: i) the totality of the observable functional and structural characteristics of an organism as determined by interaction of the
- 20 genotype of the organism with the environment in which it exists, ii) any particular characteristic or set of characteristics of an organism so determined and iii) a group of organisms exhibiting the same set of such characteristics.

- Clinical trialing of a new drug in the human population is an expensive and protracted process. Late failure of a putative drug has a significant impact on the profitability of the developer, while withdrawal of a drug after its launch on the open market has an even greater impact on the valuation and reputation of a pharmaceutical company. Phenotyping of a clinical trial group is therefore potentially very valuable in understanding how individuals respond beneficially or
- 25 adversely to a new drug. Using volunteer patients of defined phenotypes for clinical trials facilitate the design of clinical phase I and II protocols. Further, the interpretation of clinical data and potential adverse drug reactions during the trial can be reduced.
- 30

Therapeutic efficacy of a drug is dependent on if and how individuals respond to the administered drug. On the basis of the extent to which a therapeutic drug is metabolised, individuals might be characterised as being extensive, normal or poor metabolisers of a therapeutic drug.

5

In normal metabolisers, steady-state drug levels are within the expected therapeutic range and toxic effects are absent, whilst in extensive metabolisers, steady-state drug levels are sub-therapeutic, which can lead to no drug effect at all. In poor metabolisers, steady-state drug levels are larger than expected and these individuals are thus susceptible to undesired toxicity or other adverse effects of the drug. Thus, phenotyping of an individual receiving therapeutic drug treatment is valuable in understanding how individuals respond to certain drugs and drug doses and it is potentially helpful in determining adequate drugs and drug doses in order to achieve optimal therapeutic results.

15

Metabolism and transport of drug molecules in the human or non-human animate body are governed by certain proteins, e.g. enzymes or transporter proteins. The determination of the activity of said proteins can be used to phenotype individuals. Cytochrome P 450 (CYP450) plays a key role in the metabolism of drugs. The members of the CYP450 superfamily of oxidases show a common catalytic mechanism but individual isoenzymes have divergent substrate specificity. In order to assess the multiplicity of the CYP450 isoenzymes it is favourable to study metabolism using several different probe compounds, which act as substrates for the different CYP450 isoenzymes.

25

R. J. Scott et al., Rapid Commun. Mass Spectrom. 13, 1999, 2305-2319 describe the use of a "cocktail" of multiple probe drugs for studying the *in vitro* metabolism of said cocktail in human urine or plasma samples upon addition of the enzyme β -glucuronidase. After reaction, the samples were worked up by solid phase extraction and analysed by liquid chromatography and mass spectrometry (LC/MS/MS). The disadvantage of this method is that work-up of the samples is time consuming. Moreover, due to reduced recovery of the probe drugs and their metabolites after solid phase extraction it might be difficult to detect small amounts of metabolites. Another disadvantage is that any small change in the method itself requires a careful

30

validation. Moreover, MS analysis is a destructive technique and the sample used for the analysis could not be used for other purpose (e.g. further analysis with different methods) afterwards.

- 5 In WO-A-00/35900 several probe drugs comprising phenolic dyes are used as optical probes or sensors for *in vitro* screening assays of the activity of CYP450 isoenzymes. The disadvantage with this method is that the addition of dyes may influence the metabolic breakdown. Moreover, optical measurements may not be sufficiently specific due to, e.g. dye leakage, dye compartmentalisation or quenching
10 of signals. Due to the lack of specificity of current dyes, the method requires the use of single expressed isoenzymes. Although the method provides an indication of potential drug-drug interactions, it is far away from the real *in vivo* situation. Thus, the method can only be employed as an initial screening method.
- 15 K. Akira et al., Drug Metab. Dispos 29, 2001, 903-907 describe the use of ^{13}C -labelled antipyrine as an *in vivo* probe to evaluate some CYP450 isoenzymes using ^{13}C -NMR spectroscopy. Due to the reduced sensitivity of conventional ^{13}C -NMR spectroscopy, the probe drug has to be administered in large amounts leading to potential risk of adverse drug effects in the patient.
- 20 WO-A-01/96895 describes a method for obtaining information regarding the fate of a test compound in a biological system by enhancing the nuclear polarisation of an NMR active nuclei present in the test compound (hyperpolarisation) prior to NMR analysis.
- 25 There was a need for a fast and simple method for determining the activity of proteins responsible for transport and metabolism *in vivo*, which in turn would allow phenotyping of individuals.
- 30 The present invention provides a method for determining *in vivo* protein activity comprising
- a) hyperpolarising the NMR active nuclei of samples collected from a human or non-human animate body preadministered with at least one probe compound containing at least one NMR active nuclei and

- b) analysing said samples by NMR spectroscopy.

In the context of the present invention, "protein" means all proteins whose activity can be influenced by a probe compound acting e.g. as a substrate, inducer or inhibitor of said proteins. Preferred proteins are enzymes and transporter proteins, e.g. NADPH quinone oxidoreductases, CYP450, N-acetyltransferase, glutathione transferase, thiomethyltransferase, thiopurine methyltransferase, sulfotransferase, UDP-glucuronosyl transferase, pseudocholinesterase, serotonin transport protein, ATP binding cassette (ABC's) and p-glycoprotein. In a particularly preferred embodiment, CYP450 activity is determined.

The data acquired in step b) can be used to determine protein activity in a number of ways, e.g. by determining the rate of disappearance of the probe compound from samples like urine or plasma with time. As this is a difficult and time consuming task, calculating the ratio of the probe compound to their metabolites at one or more selected time points is preferred (determination of metabolic ratio).

Another aspect of the present invention is a method for determining *in vivo* protein activity comprising

- a) administering at least one probe compound containing at least one NMR active nuclei to a human or non-human animate body
- b) collecting samples from said human or non-human animate body
- c) hyperpolarising the NMR active nuclei of said samples, and
- d) analysing said samples by NMR spectroscopy.

Yet another aspect of the present invention is a method for determining *in vivo* protein activity comprising

- a) selecting at least one probe compound containing at least one NMR active nuclei
- b) administering said probe compound to a human or non-human animate body
- c) collecting samples from said human or non-human animate body
- d) hyperpolarising the NMR active nuclei of said samples, and
- e) analysing said samples by NMR spectroscopy.

According to the method of the invention, at least one probe compound containing at least one NMR active nuclei is administered to a human or non human animate body or a human or non human animate body preadministered with at least one probe
5 compound containing at least one NMR active nuclei is used in the method according to the invention.

In a preferred embodiment, at least two probe compounds, each containing at least one NMR active nuclei, are used. This embodiment is especially useful when the
10 protein activity of an enzyme family or of a family of transporter proteins is to be determined. It is thus possible to choose several probe compounds, which influence the activity of several family members, e.g. different isoenzymes.

The selection of the at least one probe compound is dependent on which protein
15 activity is to be determined. Thus, one or more probe compounds may be used in the method according to the invention. If more than one probe compound (i.e. several probe compounds) are used in the method according to the invention, the method according to the invention may be repeatedly carried out using a single probe compound each time or it may be carried out using the several probe compounds in
20 one approach, e.g. as a mixture of several probe compounds. If more than one probe compound is used, suitably at least 3 probe compounds are used, more suitably at least 4 and preferably at least 7 probe compounds.

If the protein activity of an enzyme family is to be determined, the probe compounds
25 should be selected in such a way that preferably all or at least most of the isoenzymes of a certain enzyme family are addressed with specific probe compounds. Preferably, probe compounds and their metabolites show a well-dispersed NMR spectrum in order to distinguish clearly between the different probe compounds and their metabolites.

30

Preferably, safety and availability of the probe compounds used in the method of the invention is high. It is further preferred that the probe compound and its metabolites may be analysed in different types of samples collected from a human or non-human animate body, particularly in different types of biofluids like urine and plasma.

If the enzyme to be addressed in the method according to the invention is CYP450, a number of possible probe compounds for different isoenzymes are known (see for example R. J. Scott et al., *Rapid Commun. Mass Spectrom.* 13, 1999, 2305-2319 or
5 R.F. Frye et al., *Clin. Pharmacol. Ther.* 62, 1997, 365). Said probe compounds are preferably selected according to the above-mentioned aspects.

Suitably, the probe compounds are substrates, inducers or inhibitors for CYP450, preferably for CYP450 isoenzymes selected from the group consisting of CYP1A2,
10 CYP2A6, CYP2B6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.

Preferred probe compounds for determining CYP450 activity are selected from the group consisting of phenacetin, coumarin, tolbutamide, phenytoin, mephenytoin, S-mephenytoin, bufuralol, chlorzoxazone, midazolam, caffeine, dapsone, diclofenac,
15 debrisoquine, bupropion, antipyrine, dextromethorphan, warfarin, diazepam, alprazolam, triazolam, flurazepam, chlodiazepoxide theophylline, phenobarbital propranolol, metoprolol, labetalol, nifedipine, digitoxin, quinidine, mexiletine, lidocaine, imipramine, flurbiprofen, omeprazole, terfenadine, furafylline, codeine, nicotine, sparteine, erythromycin, benzoylecholine, butrylcholine, paraoxon, para-
20 aminosalicylic acid, isoniazid, sulfamethazine, 5-fluorouracil, trans-stilbene oxide, D-penicillamine, captopril, ipomeanol, cyclophosphamide, halothane, zidovudine, testosterone, acetaminophen, hexobarbital, carbamazepine, cortisol, oltipraz, cyclosporin A and paclitaxel.

25 Particularly preferred probe compounds for determining CYP450 activity are selected from the group consisting of phenacetin, coumarin, tolbutamide, mephenytoin, S-mephenytoin, bufuralol, chlorzoxazone, midazolam, caffeine, dapsone, diclofenac, debrisoquine, bupropion, antipyrine and dextromethorphan.

30 If N-acetyltransferase activity is to be determined, preferred probe compounds are selected from the group consisting of sulfathiazole, dapsone, isoniazid, sulfamethoxazole, hydrazaline, caffeine and procainamide.

If glutathione-S-transferase activity is to be determined, preferred probe compounds are selected from the group consisting of phenobarbital and 3-methyl-cholanthrene. Are selected from the group consisting of phenobarbital, 3-methyl-cholanthrene and oltipraz.

5

If thiopurine methyltransferase activity is to be determined, preferred probe compounds are selected from the group consisting of azathioprine, mercaptopurine and thioguanine.

- 10 If thiomethyltransferase activity is to be determined, preferred probe compounds are selected from the group consisting of captopril and penicillamine.

If UDP-glucuronosyl transferase activity is to be determined, preferred probe compounds are selected from the group consisting of bilirubin and barbiturates.

15

If p-glycoprotein activity is to be determined, preferred probe compounds are selected from the group consisting of cancer drugs like paclitaxel and of immunosuppressive drugs like cyclosporin A.

- 20 The probe compounds used in the method according to the invention contain at least one NMR active nuclei, i.e. nuclei with non-zero nuclear spin. Preferred nuclei are ^{13}C , ^{15}N , ^{31}P , ^{19}F , and/or ^1H . Isotopically enriched probe compounds can be employed. If non-enriched probe compounds are employed, probe compounds containing nuclear species occurring at high natural abundance such as ^{31}P , ^{19}F ,
25 and/or ^1H are preferably employed. However, isotopically enriched probe compounds, preferably enriched with non-radioactive isotopes, are preferably used in the method according to the invention as the isotopic enrichment has substantially no effect on the therapeutic efficacy of the probe compound and the NMR detection is strongly facilitated.

30

The enrichment may include either selective enrichments of one or more sites within the probe compound molecule or uniform enrichment of all sites. Preferably, the probe compounds are isotopically enriched in only one position of the molecule. Enrichment can be achieved by chemical synthesis or biological labelling. Suitably,

a probe compound for use in the method according to the invention is an organic compound isotopically enriched in only one position of the molecule with an enrichment of at least 10%, most suitably at least 25%, preferably at least 75%, most preferably at least 90%, ideally approaching 100%.

5

In a preferred embodiment of the present invention, the probe compounds are enriched with ^{13}C and/or ^{15}N , preferably with ^{13}C or ^{15}N , particularly preferred with ^{13}C as for higher sensitivity and a broader choice of labelling. In a further preferred embodiment, all probe compounds are enriched with the same NMR active nuclei.

10 Thus, it is possible to collect information in a single NMR analysis.

15

The optimal position for isotopic enrichment in the probe compound depends on the relaxation time of the NMR active nuclei. Preferably, probe compounds are isotopically enriched in positions with long T1 relaxation time. In a preferred embodiment, ^{13}C enriched probe compounds enriched at a carboxyl, a carbonyl or a quaternary C-atom, are used. Further, the probe compounds are preferably isotopically enriched in positions of the molecule where, upon metabolism, structural changes take place. This leads to greater chemical shift differences between the probe compound and its metabolites, which leads to better-dispersed NMR spectra.

20

Labelling in two or more positions may facilitate the interpretation of complex NMR spectra.

25

The preadministration or administration of the at least one probe compound to the human or non-human animate body may be carried out in different ways. If more than one probe compound is used in the method according to the invention, the probe compounds may either be administered sequentially or as a mixture of probe compounds.

30

If the probe compounds are administered as a mixture, probe compounds can be mixed and subsequently dissolved or dispersed in a solvent or a solvent mixture, which then can be directly used for administration or which can be further treated before the administration. Alternatively, each probe compound or some of the probe compounds are dissolved or dispersed in a solvent or a solvent mixture first and then a mixture of the dissolved / dispersed probe compounds is prepared. In order to

achieve proper mixing, common mixing techniques such as stirring, bubbling, agitation, vortexing or sonification may be used. In another embodiment, mixtures of solid probe compounds may be used for preadministration/administration.

- 5 The solvents or solvent mixtures used for dissolving or dispersing the probe compounds are preferably physiologically tolerable solvents.

The probe compounds are preferably formulated in conventional pharmaceutical or veterinary administration forms. If the probe compounds in solution are used for
10 preadministration/administration, then they may be in the form of a suspension, dispersion, slurry etc., for example in an aqueous vehicle such as water. If the probe compounds in solid form are used for preadministration/administration, then they may be in the form of tablets or powder.

- 15 The probe compounds used in the method according to the invention may further contain pharmaceutically acceptable diluents and excipients and formulation aids, e.g. stabilisers, antioxidants, osmolality adjusting agents, buffers or pH-adjusting agents. For injection, a sterile solution or suspension of the probe compounds is most preferred. For parental administration, a carrier medium, which is preferably isotonic
20 or somewhat hypertonic, is preferred.

The probe compounds are preferably administered into the vasculature or directly into an organ or muscle tissue as well as subdermally or subcutaneously. In another preferred embodiment, the probe compounds are administered via non-parental route
25 such as transdermal, nasal, sub-lingual or into an external body cavity e.g. orally in the gastro-intestinal tract.

- Due to the sensitivity of the method according to the invention, sub-therapeutic administration is possible which strongly minimises the risk of adverse effects of the
30 probe compounds. Thus, the dosage for preadministration or administration is suitably therapeutic or sub-therapeutic, sub-therapeutic dosages are preferred.

The term "samples" means one single sample or multiple samples. Samples may be collected once, at time intervals or continuously (dynamic studies).

Samples that may be collected include tissue or cell samples, faeces, biofluids including but not limited to blood, blood plasma, lymph, urine, semen, breast milk, cerebro-spinal fluid, sweat, lachrymal or parotid secretions or lavage. Preferably, samples collected are biofluids, particularly preferably blood, blood plasma or urine.

If the method according to the invention is used for determining the *in vivo* activity of CYP450 isoenzymes, collected samples from human or non-human animate bodies are preferably blood, blood plasma and urine.

10

The collected samples may be further processed, e.g. in order to separate cells from liquids. Thus, blood may be treated in order to obtain blood plasma. The samples may be purified prior to hyperpolarisation and/or analysis but this is not always necessary. An important advantage of the method according to the invention is that analysis can be carried out directly on the crude sample without the need for fractionation, purification or concentration steps.

If the protein activity is determined by calculating the rate of disappearance of the probe compounds, a reference standard may conveniently be included in the sample before hyperpolarisation. Inclusion of said standard allows the determination of the concentration of the probe compounds and their metabolites. Preferably, one standard is added. Suitable standards are simple molecules comprising signals, which do not interfere with the signals from the probe compounds, and their metabolites. Preferred standards do comprise only one signal. Conveniently, a chemical shift reference is added to the sample before hyperpolarisation.

20
25

There are several ways for hyperpolarising NMR active nuclei, preferred ways are polarisation transfer from a noble gas, "brute force", DNP and spin refrigeration, all explained below.

30

A preferred way for hyperpolarising the NMR active nuclei containing probe compounds according to the invention is the polarisation transfer from a hyperpolarised noble gas. Noble gases having non-zero nuclear spin can be hyperpolarised, i.e. have their polarisation enhanced over the equilibrium

polarisation, e.g. by the use of circularly polarised light. A hyperpolarised noble gas, preferably ^3He or ^{129}Xe , or a mixture of such gases may be used according to the present invention to effect hyperpolarisation of the NMR active nuclei present in the probe and/or test compounds. The hyperpolarisation may also be achieved by using
5 an artificially enriched hyperpolarised noble gas, preferably ^3He or ^{129}Xe . The hyperpolarised gas may be in the gas phase, it may be dissolved in a liquid, or the hyperpolarised gas itself may serve as a solvent. Alternatively, the gas may be condensed onto a cooled solid surface and used in this form, or allowed to sublime. Either of these methods may allow the necessary intimate mixing of the
10 hyperpolarised gas with the target to occur. In some cases, liposomes or microbubbles may encapsulate the hyperpolarised noble gas.

Another preferred way for hyperpolarising the NMR active nuclei containing probe compounds according to the invention is that polarisation is imparted to said NMR
15 active nuclei by thermodynamic equilibration at a very low temperature and high field. Hyperpolarisation compared to the operating field and temperature of the NMR spectrometer is effected by use of a very high field and very low temperature (brute force). The magnetic field strength used should be as high as possible, suitably higher than 1 T, preferably higher than 5 T, more preferably 15 T or more and
20 especially preferably 20 T or more. The temperature should be very low, e.g. 4.2 K or less, preferably 1.5 K or less, more preferably 1.0 K or less, especially preferably 100 mK or less.

Another preferred way for hyperpolarising the NMR active nuclei containing probe
25 compounds according to the invention is the DNP (dynamic nuclear polarisation) method effected by a DNP agent. DNP mechanisms include the Overhauser effect, the so-called solid effect and the thermal mixing effect. Most known paramagnetic compounds may be used as DNP agents, e.g. transition metals such as chromium (V) ions, magnesium (II) ions, organic free radicals such as nitroxide radicals and trityl
30 radicals (WO-A-98/58272) or other particles having associated free electrons. Preferably, radicals with low relaxivity are used as DNP agents. Where the DNP agent is a paramagnetic free radical, the radical may be conveniently prepared *in situ* from a stable radical precursor by a radical-generating step shortly before the polarisation, or alternatively by the use of ionising radiation. During the DNP

process, energy, normally in the form of microwave radiation, is provided, which will initially excite the paramagnetic species. Upon decay to the ground state, there is a transfer of polarisation to the NMR active nuclei of the target material. The method may utilise a moderate or high magnetic field and a very low temperature, e.g. by carrying out the DNP process in liquid helium and a magnetic field of about 1 T or above. Alternatively, a moderate magnetic field and any temperature at which sufficient NMR enhancement is achieved in order to enable the desired studies to be carried out may be employed. The method may be carried out by using a first magnet for providing the polarising magnetic field and a second magnet for providing the primary field for MR spectroscopy.

Another preferred way for hyperpolarising the NMR active nuclei containing probe and/or test compounds according to the invention is the spin refrigeration method. This method covers spin polarisation of a solid compound or system by spin refrigeration polarisation. The system is doped with or intimately mixed with suitable paramagnetic materials such as Ni^{2+} , lanthanide or actinide ions in crystal form with a symmetry axis of order three or more. The instrumentation is simpler than required for DNP with no need for a uniform magnetic field since no resonance excitation field is applied. The process is carried out by physically rotating the sample around an axis perpendicular to the direction of the magnetic field. The prerequisite for this method is that the paramagnetic species has a highly anisotropic g-factor. As a result of the sample rotation, the electron paramagnetic resonance will be brought in contact with the nuclear spins, leading to a decrease in the nuclear spin temperature. Sample rotation is carried out until the nuclear spin polarisation has reached a new equilibrium.

Some of the hyperpolarisation techniques described above, e.g. DNP, brute force or spin refrigeration transfer, are only effective when transferring polarisation to the solid state. If the sample is not solid, it may conventionally be frozen in an appropriate solvent or solvent mixture prior to hyperpolarisation by one of the methods that needs to be carried out in the solid state. Solvent mixtures have been found to be particularly suitable, especially if the mixture forms an amorphous glass, preferably by use of glycerol. Such a matrix of amorphous glass is preferably

employed in DNP hyperpolarisation to ensure homogenous intimate mixing of radical and target in the solid.

5 The degree of hyperpolarisation of the NMR active nuclei according to the invention can be measured by its enhancement factor compared to thermal equilibrium at spectrometer field and temperature. Suitably the enhancement factor is at least 10, preferably at least 50 and more preferably at least 100. However, methods according to the invention where even smaller enhancements are achieved may still be performed usefully due to the shorter time needed for the total measurement
10 compared with methods described in the prior art. If the enhancement is reproducible and the hyperpolarisation/NMR analysis can be repeated, the signal to noise ratio of a NMR signal can be improved. In such a case, the minimum NMR enhancement factor required depends on the hyperpolarisation technique and the concentration of the probe/test compound and their metabolites. The enhancement has to be large
15 enough so that the NMR signal from the probe/test compound and their metabolites can be detected. In this context, it is clear that an enhancement of 10 or less than 10 that is achievable in a multi-shot experiment may be very useful due to the time saved in data acquisition compared with conventional NMR.

20 According to the method of the invention, hyperpolarised samples are analysed using NMR spectroscopy. The analysis may be carried out by continuous monitoring or as a single discrete measurement or as a series of discrete measurements that may be carried out at suitable intervals over time. Thus, it is possible to identify many and preferably all changes in metabolism and appearance of individual metabolites of the
25 probe compounds.

The hyperpolarised sample may as well be further diluted or mixed with suitable solvents or solvent mixtures for NMR spectroscopy, depending on which kind of NMR analysis, e.g. liquid or solid phase NMR spectroscopy, is to be applied.

30

After hyperpolarisation, it is desirable to preserve as much as possible of the polarisation prior to NMR analysis. Some of the hyperpolarisation techniques described above, e.g. DNP, brute force, or spin refrigeration transfer, are only effective when transferring polarisation to the solid state. However, it is often desired

to investigate the NMR spectrum of a sample in the liquid state, in order to improve spectral resolution and sensitivity. Alternatively, line-narrowing techniques like Magic Angle Spinning (MAS) can be employed to increase spectral resolution of NMR in the solid state and enable low temperature NMR analysis.

5

If a liquid state NMR technique is to be employed, the hyperpolarised sample is preferably rapidly removed from the polarisation chamber and then dissolved in a suitable solvent. It is advantageous to use solvents, which do not interfere with the spectra produced in the analysis step, or solvents, which keep a stable chemical environment and prolong the T1 relaxation time. Deuterated solvents such as D₂O or mixtures of methanol and acid, preferably with an excess of methanol, are particularly suitable. Stirring, bubbling, sonification or other known techniques can be used to improve the speed of dissolution. Suitably, the temperature and the pH of the solution are maintained to allow optimal dissolution and a long nuclear relaxation time.

10
15

Preferably, the sample or a solution thereof is kept in a holding field throughout the period between polarisation and analysis in order to prevent relaxation. A holding field provides a higher field than the Earth's magnetic field and suitably higher than 10 mT. It is suitably uniform in the region of the sample and the optimal conditions will depend on the nature of the sample.

20

The sample or a solution thereof is subsequently transferred for examination, preferably by standard solution phase NMR analysis. The transfer process is manually or automated, preferably automated. Alternatively, the hyperpolarisation step and optional subsequent dissolution step(s) are suitably integrated into a single automated unit. In another suitable embodiment, hyperpolarisation and optional dissolution step(s) are automated and NMR detection hardware is also housed within the same single fully integrated unit.

25

30

Alternatively, where a solid state NMR technique is to be used, the solid state sample may be hyperpolarised, e.g. by DNP, brute force, spin refrigeration transfer or any other method that will work in the solid state at low temperature. Subsequently, the hyperpolarised sample will be moved into a solid state MAS NMR

probe. The movement is suitably rapid and is preferably carried out via lifting or ejection. The sample in the NMR probe will then be spun so that high resolution solid state NMR spectroscopy can be carried out. The entire process can be automated and will preferably be carried out in an integrated unit.

5

In a preferred aspect of the invention is a method for determining the *in vivo* activity of CYP450 comprising

- a) hyperpolarising the NMR active nuclei of samples collected from a human or non-human animate body preadministered with at least one, preferably at least 3
10 ¹³C-isotopically enriched probe compounds selected from the group consisting of phenacetin, coumarin, tolbutamide, phenytoin, mephenytoin, S-mephenytoin, bufuralol, chlorzoxazone, midazolam, caffeine, dapsone, diclofenac, debrisoquine, bupropion, antipyrine, dextromethorphan, warfarin, diazepam, alprazolam, triazolam, flurazepam, chlodiazepoxide theophylline, phenobarbital
15 propranolol, metoprolol, labetalol, nifedipine, digitoxin, quinidine, mexiletine, lidocaine, imipramine, flurbiprofen, omeprazole, terfenadine, furafylline, codeine, nicotine, sparteine, erythromycin, benzoylcholine, butylcholine, paraoxon, para-aminosalicylic acid, isoniazid, sulfamethazine, 5-fluorouracil, trans-stilbene oxide, D-penicillamine, captopril, ipomeanol, cyclophosphamide,
20 halothane, zidovudine, testosterone, acetaminophen, hexobarbital, carbamazepine, cortisol, oltpiraz, cyclosporin A and paclitaxel, and
b) analysing the samples by ¹³C-NMR spectroscopy.

In a preferred embodiment of the method described in the paragraph above, the
25 samples collected from the human or non-human animate body are urine and/or blood samples.

Yet in another preferred embodiment of the method described in said paragraph, the at least one, preferably at least 3 ¹³C-isotopically enriched probe compounds are
30 selected from the group consisting of phenacetin, coumarin, tolbutamide, mephenytoin, S-mephenytoin, bufuralol, chlorzoxazone, midazolam, caffeine, dapsone, diclofenac, debrisoquine, bupropion, antipyrine and dextromethorphan. The selected probe compounds are preferably ¹³C enriched in positions with long T1 relaxation time.

Yet in another preferred embodiment of the method described in said paragraph, the hyperpolarisation of the NMR active nuclei of the at least one probe compound is carried out by using the DNP method.

5

Hence, a particularly preferred aspect of the invention is a method for determining the *in vivo* activity of CYP450 comprising

- a) DNP-hyperpolarising the NMR active nuclei of urine and/or blood samples collected from a human or non-human animate body preadministered with at least one, preferably at least 3 ^{13}C -isotopically enriched probe compounds selected from the group consisting of phenacetin, coumarin, tolbutamide, mephenytoin, S-mephenytoin, bufuralol, chlorzoxazone, midazolam, caffeine, dapsone, diclofenac, debrisoquine, bupropion, antipyrine and dextromethorphan, the probe compounds being isotopically enriched in positions with long T1 relaxation time, and
- b) analysing the samples by ^{13}C -NMR spectroscopy.

10

15

The method of the invention can be used for phenotyping of individuals, e.g. for phenotyping of a clinical trial group or for phenotyping of individuals who will receive therapeutic drug treatment. If the method according to the invention is used for phenotyping of a clinical trial group, protein activity according to the invention is determined in the volunteer patients. According to the data and information gained by the method of the invention, volunteer patients are classified into groups of individuals showing similar biological behaviour towards the probe compounds. If the method according to the invention is used for phenotyping of an individual who will receive therapeutic drug treatment, the data and information gained by the method of the invention may be compared to data and information gained by the method of the invention but obtained from other individuals.

20

25

- 30 If the method according to the invention is used for phenotyping, protein activity, e.g. enzyme activity may be determined by calculating the metabolic ratio between the probe compounds and their metabolites. In order to evaluate a metabolic ratio from a particular individual, it may be compared to statistical material. Such statistical material may be obtained by calculating the metabolic ratio between probe

compounds and their metabolites in a large number of individuals. A frequency distribution histogram may be established (number of individuals vs. metabolic ratio). If for instance a polymorphism is present in the enzymatic pathway under evaluation, then the distribution will be bimodal. This bimodal distribution reflects
5 that a subset of the population is unable to or suffers from some deficiency in metabolising the probe compounds through the particular enzymatic pathway. An antimode (a definitive separating value) will separate the individual modes of the distribution. Based on this bimodal population distribution, it is possible to define a
10 phenotype by being able to distinguish between two populations, e.g. the poor metabolisers and the extensive metabolisers. The antimode serves as a threshold for distinguishing between the two phenotypes. Metabolic ratio values above the antimode will indicate a poor metaboliser whereas metabolic ratio values below the antimode will indicate an extensive metaboliser phenotype.

- 15 Another aspect of the invention is a method as described above wherein from said analysis of step b) an NMR pattern I is generated. Said NMR pattern is preferably stored electronically, e.g. in a database.

Subsequently said method comprises the further steps of

- 20 c) hyperpolarising the NMR active nuclei of samples collected from a human or non-human animate body preadministered with said at least one probe compound and at least one putative drug
d) analysing the samples by NMR spectroscopy and hereby generating an NMR pattern II, and
25 e) comparing the NMR patterns I and II thus identifying distinctions in the NMR pattern II which are due to the administration of the putative drug.

Hence, another aspect of the invention is a method for determining *in vivo* protein activity comprising

- 30 a) hyperpolarising the NMR active nuclei of samples collected from a human or non-human animate body preadministered with at least one probe compound containing at least one NMR active nuclei,
b) analysing said samples by NMR spectroscopy and hereby generating an NMR pattern I,

- c) hyperpolarising the NMR active nuclei of samples collected from a human or non-human animate body preadministered with said at least one probe compound and at least one putative drug,
- d) analysing said samples by NMR spectroscopy and hereby generating an NMR pattern II,
- e) comparing the NMR patterns I and II thus identifying distinctions in the NMR pattern II, which are due to the administration of the putative drug.

Steps a) to d) are carried out as described above and the NMR pattern II obtained in step d) is preferably stored electronically, e.g. in a database. The comparison of the NMR patterns I and II is preferably carried out using algorithmic analysis, typically by employing a computer with appropriate software.

The such acquired NMR patterns allow the determination of the change of *in vivo* protein activity upon administration of the probe compounds a) alone (NMR pattern I) and the administration of the probe compounds in combination with a putative drug (NMR pattern II). Thus, the possible influence of a putative drug can be determined.

This method may be used to study drug-drug interaction, which is an important feature in the development of new drugs. The term "drug-drug interaction" refers to a new chemical entity being potentially interacting with already existing pharmacological drugs. As many diseases require treatment with multiple drugs, drug-drug interaction may result in adverse side effects which can lead to potential new drugs being withdrawn. Although various *in vitro* techniques have been introduced to evaluate the potential for such interactions, predicting the *in vivo* importance of such interactions proves to be difficult.

The above-mentioned method can be repeated for several single putative drugs or several putative drugs. Thus, a first NMR pattern related to a first set of probe compounds of a human or non-human animate being can be stored and compared with subsequently obtained NMR patterns related to the first set of probe compounds in combination with several single putative drugs or several putative drugs.

Another aspect of the present invention is a mixture comprising at least two probe compounds, all probe compounds being enriched with ^{13}C and/or ^{15}N NMR active nuclei. Preferably, said mixture is used in the methods described above, particularly preferably for metabolic phenotyping.

5

Suitably, said mixture comprises at least 3 probe compounds, most suitably at least 4 and preferably at least 7 probe compounds.

10 In a preferred embodiment, the probe compounds in said mixture are enriched with ^{13}C or ^{15}N , particularly preferred with ^{13}C . In a further preferred embodiment, the probe compounds in said mixture are all enriched with the same NMR active nuclei. Preferably, the compounds are enriched in a position with long T1 relaxation time. If the compounds are ^{13}C enriched, probe compounds enriched at a carboxyl, a carbonyl or a quaternary C-atom, are preferred.

15

In a preferred embodiment, said mixture comprises probe compounds, which interact with the proteins selected from the group consisting of NADPH quinone oxireductases, CYP450, N-acetyltransferase, glutathione transferase, thiomethyltransferase, thiopurine methyltransferase, S-methyltransferase, sulfotransferase, 20 UDP-glucuronosyl transferase, pseudocholinesterase, serotonin transport protein, ATP binding cassette (ABC's) and p-glycoprotein. "Interaction" means that the activity of said proteins is influenced by the probe compounds, e.g. the probe compounds act as a substrate, an inducer or an inhibitor of said proteins.

25 In a preferred embodiment, the mixture according to the invention comprises compounds which interact with CYP450, particularly preferably with CYP450 isoenzymes selected from the group consisting of CYP1A2, CYP2A6, CYP2B6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.

30 Preferably, the mixture according to the invention comprises probe compounds selected from the group consisting of phenacetin, coumarin, tolbutamide, phenytoin, mephentyoin, S-mephentyoin, bufuralol, chlorzoxazone, midazolam, caffeine, dapsone, diclofenac, debrisoquine, bupropion, antipyrine, dextromethorphan, warfarin, diazepam, alprazolam, triazolam, flurazepam, chlodiazepoxide

theophylline, phenobarbital propranolol, metoprolol, labetalol, nifedipine, digitoxin, quinidine, mexiletine, lidocaine, imipramine, flurbiprofen, omeprazole, terfenadine, furafylline, codeine, nicotine, sparteine, erythromycin, benzoylcholine, butrylcholine, paraoxon, para-aminosalicylic acid, isoniazid, sulfamethazine, 5-fluorouracil, trans-stilbene oxide, D-penicillamine, captopril, ipomeanol, cyclophosphamide, halothane, zidovudine, testosterone, acetaminophen, hexobarbital, carbamazepine, cortisol, oltipraz, cyclosporin A and paclitaxel. Such a mixture is useful for the determination of CYP450 activity.

10 Particularly preferably, the mixture according to the invention comprises probe compounds selected from the group consisting of phenacetin, coumarin, tolbutamide, mephenytoin, S-mephenytoin, bufuralol, chlorzoxazone, midazolam, caffeine, dapsone, diclofenac, debrisoquine, bupropion, antipyrine and dextromethorphan. Such a mixture is especially useful for the determination of CYP450 activity.

15

In a further preferred embodiment, the mixture according to the invention comprises probe compounds that interact with N-acetyltransferase. Thus, the mixture according to the invention preferably comprises probe compounds selected from the group consisting of sulfathiazole, dapsone, isoniazid, sulfamethoxazole, hydrazaline, caffeine and procainamide. Such a mixture is useful for the determination of N-acetyltransferase activity.

20

In a further preferred embodiment, the mixture according to the invention comprises probe compounds that interact with glutathione-S-transferase. Thus, the mixture according to the invention preferably comprises probe compounds selected from the group consisting of phenobarbital, oltipraz and 3-methyl-cholanthrene. Such a mixture is useful for the determination of glutathione-S-transferase activity.

25

In a further preferred embodiment, the mixture according to the invention comprises probe compounds that interact with thiopurine methyltransferase. Thus, the mixture according to the invention comprises probe compounds selected from the group consisting of azathioprine, mercaptopurine and thioguanine. Such a mixture is useful for the determination of thiopurine methyltransferase activity.

30

In a further preferred embodiment, the mixture according to the invention comprises probe compounds that interact with thiomethyltransferase. Thus, the mixture according to the invention comprises probe compounds selected from the group consisting of captopril and penicillamine. Such a mixture is useful for the determination of thiomethyltransferase activity.

In a further preferred embodiment, the mixture according to the invention comprises probe compounds that interact with UDP-glucuronosyl transferase. Thus, the mixture according to the invention comprises probe compounds selected from the group consisting of bilirubin and barbiturates. Such a mixture is useful for the determination of UDP-glucuronosyl transferase activity.

In a further preferred embodiment, the mixture according to the invention comprises probe compounds that interact with p-glycoprotein. Thus, the mixture according to the invention comprises probe compounds selected from the group consisting of cancer drugs like paclitaxel and of immunosuppressive drugs like cyclosporin A. Such a mixture is useful for the determination of p-glycoprotein activity.

In a preferred embodiment, the mixtures according to the invention further comprise at least one putative drug. These mixtures are preferably useful to evaluate potential drug-drug interaction.

Hence, another aspect of the invention is a mixture comprising at least two probe compounds, all probe compounds being enriched with ^{13}C and/or ^{15}N NMR active nuclei and at least one putative drug.

In a preferred embodiment, said mixture comprises at least one putative drug and said at least two probe compounds are probe compounds, which interact with the proteins selected from the group consisting of NADPH quinone oxidoreductases, CYP450, N-acetyltransferase, glutathione transferase, thiomethyltransferase, thiopurine methyltransferase, sulfotransferase, UDP-glucuronosyl transferase, pseudocholinesterase, serotonin transport protein, ATP binding cassette (ABC's) and p-glycoprotein. "Interaction" means that the activity of said proteins is influenced by

the probe compounds; e.g. the probe compounds act as a substrate, an inducer or an inhibitor of said proteins.

- In a preferred embodiment, the mixture according to the invention comprises at least one putative drug and said at least two probe compounds are probe compounds, which interact with CYP450, particularly preferably with CYP450 isoenzymes selected from the group consisting of CYP1A2, CYP2A6, CYP2B6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.
- Preferably, the mixture according to the invention comprises at least one putative drug and said at least two probe compounds are probe compounds selected from the group consisting of phenacetin, coumarin, tolbutamide, phenytoin, mephentytoin, S-mephentytoin, bufuralol, chlorzoxazone, midazolam, caffeine, dapsone, diclofenac, debrisoquine, bupropion, antipyrine, dextromethorphan, warfarin, diazepam, alprazolam, triazolam, flurazepam, chlodiazepoxide theophylline, phenobarbital propranolol, metoprolol, labetalol, nifedipine, digitoxin, quinidine, mexiletine, lidocaine, imipramine, flurbiprofen, omeprazole, terfenadine, furafylline, codeine, nicotine, sparteine, erythromycin, benzoylcholine, butrylcholine, paraoxon, para-aminosalicylic acid, isoniazid, sulfamethazine, 5-fluorouracil, trans-stilbene oxide, D-penicillamine, captopril, ipomeanol, cyclophosphamide, halothane, zidovudine, testosterone, acetaminophen, hexobarbital, carbamazepine, cortisol, oltipraz, cyclosporin A and paclitaxel. Such a mixture is useful for studying drug-drug interaction.
- Particularly preferably, the mixture according to the invention comprises at least one putative drug and said at least two probe compounds are probe compounds selected from the group consisting of phenacetin, coumarin, tolbutamide, mephentytoin, S-mephentytoin, bufuralol, chlorzoxazone, midazolam, caffeine, dapsone, diclofenac, debrisoquine, bupropion, antipyrine and dextromethorphan. Such a mixture is especially useful for studying drug-drug interaction.

In a further preferred embodiment, the mixture according to the invention comprises at least one putative drug and said at least two probe compounds are probe compounds selected from the group consisting of sulfathiazole, isoniazid,

sulfamethoxazole, hydrazaline, procainamide, 3-methyl-cholanthrene, azathioprine, mercaptopurine, thioguanine, bilirubin, barbiturates, cancer drugs like paclitaxel and of immunosuppressive drugs.

- 5 Another aspect of the invention is a mixture comprising at least two probe compounds, all probe compounds being enriched with ^{13}C and/or ^{15}N NMR active nuclei for use as an agent for determining *in vivo* protein activity, whereby said agent is preferably used for phenotyping.
- 10 Yet another aspect of the invention is a mixture comprising at least two probe compounds, all probe compounds being enriched with ^{13}C and/or ^{15}N NMR active nuclei and at least one putative drug for use as an agent for determining *in vivo* protein activity, whereby said agent is preferably used for studying drug-drug interaction.
- 15 Yet another aspect of the invention is the use of a mixture comprising at least two probe compounds, all probe compounds being enriched with ^{13}C and/or ^{15}N NMR active nuclei for the manufacture of an agent for determining *in vivo* protein activity, whereby said agent is preferably used for phenotyping.
- 20 Yet another aspect of the invention is the use of a mixture comprising at least two probe compounds, all probe compounds being enriched with ^{13}C and/or ^{15}N NMR active nuclei, and at least one putative drug for the manufacture of an agent for determining *in vivo* protein activity, whereby said agent is preferably used for
- 25 studying drug-drug interaction.

Examples

Example 1


- 5 **Determination of the activity of the CYP450 isoenzymes CYP1A2, CYP2D6 and CYP2E1 using a mixture of probe compounds**

The activity of the CYP450 isoenzymes CYP1A2, CYP2D6 and CYP2E1 was determined using the following probe compounds:

- 10 • Caffeine as a substrate for CYP1A2, caffeine is primarily metabolised to paraxanthine.
- Debrisoquine as a substrate for CYP2D6, debrisoquine is primarily metabolised to 4-hydroxy-debrisoquine.
- 15 • Chlorzoxazone as a substrate for CYP2E1, chlorzoxazone is primarily metabolised to 6-hydroxy-chlorzoxazone


The compounds used were isotopically labelled at the following positions:

Caffeine:




20

Debrisoquine:



25

5 Chlorzoxazone



10

1a) Study performance

A SPD rat was sequentially injected interperitonally (ip) with

- 43.3 $\mu\text{mol/kg}$ chlorzoxazone, solubilised in 250 μl PEG 400,
- 36.9 $\mu\text{mol/kg}$ caffeine, solubilised in 10 mM sodiumphosphate buffer, pH 7.3,
- 15 0.9% NaCl and
- 41.5 $\mu\text{mol/kg}$ debrisoquine, solubilised in 10 mM sodiumphosphate buffer, pH 7.3, 0.9% NaCl.

Urine samples were collected immediately before administration and then at 1 h and 2.5 h after administration. The volume of urine collected for each period was in the
20 range of 1 to 10 ml. Blood samples were collected immediately before administration and then at 1, 2 and 3 h after administration. After collection, blood samples were spun down at 2000 rpm for 10 min. and the plasma was collected. Both, plasma and urine samples were frozen at -20°C .

25

1b) Hyperpolarisation of the collected samples and NMR analysis

A stock solution of tritylradical Tris(8-carboxyl-2,2,6,6-tetra(2-(1-hydroxyethyl))-benzo[1,2-d:4,5-d']bis(1,3)dithiole-4-yl)methyl sodium salt (428 mg, 300 μmol) in glycerol (12.61 g) was prepared. Aliquots of the stock solution (51.0 mg) were
30 mixed with 40 μl biofluid (urine or blood plasma) to give a 15 mM trityl radical solution. These solutions were dispensed as droplets into liquid nitrogen to provide

the material as vitrified pellets suitable for hyperpolarisation. The solid samples were placed in turn within the DNP magnet and hyperpolarised overnight. The samples were dissolved by injection of a mixture of methanol and acetic acid (100:1). The dissolved samples were quickly manually transferred (approx. 4 s transfer time) to a high-resolution magnet of 9.4 T and single acquisition ^{13}C -1D-NMR-spectra were acquired.

1c) Results

- 10 A large number of signals were expected for the probe compounds and their multitudes of metabolites. In addition, the biofluid matrix signals and the solvent signals were also expected to be present in the spectra.
- For caffeine, major caffeine metabolites were expected to be 1,3-dimethyl uric acid; 1, 3, 7-trimethyl uric acid and paraxanthine. Further minor caffeine metabolites were
- 15 expected to be 1-xanthine, 1, 3-xanthine; 3, 7-xanthine; 1, 3, 7-DAU; 3, 7-uric acid; 1, 7-uric acid and 1-uric acid. For debrisoquine, several metabolites including 4-hydroxy debrisoquine were present in addition to debrisoquine itself. In the urine sample collected after 3 h, only debrisoquine and 4-hydroxy debrisoquine were present. Additionally, two unknown signals were present which were possibly urine
- 20 background signals.

Quantification:

- A known amount of the unlabelled probe compounds caffeine, chlorzoxazone, debrisoquine and their primary metabolites had been spiked into SPD rat urine
- 25 samples, hyperpolarisation and NMR analysis is carried out as described above. From these experiments it was possible to estimate an enhancement factor for the carbon atoms of interest in the individual probe compounds and their metabolites. Quantification of the unknown amount of probe compound/metabolites in the biofluid samples was based on these enhancements and the known amount of probe
- 30 compound/metabolite used to generate them. The carbon signal of interest was integrated and this integral value was adjusted (division by 90, 1.1% natural abundance ^{13}C) to account for the unlabelled probe compounds used in the spiked samples compared to the isotopically enriched probe compounds used in the biofluid samples. This integral was then related to the concentration of probe compound used

- in the spiked samples and compared to the integral obtained for the individual carbon signals identified in the biofluid samples. A careful phase and baseline correction had been performed before integration and the integral window was pre-adjusted to 25 Hz in all measurements. In case of signal overlap an estimated value had been
- 5 obtained using the signal to noise ratio of the signals of interest.

The following concentration ranges were obtained:

Urine	Sample collected after	Concentration range (µg/ml)
Caffeine	1 h	4 - 5
Caffeine	2,5 h	<3
Debrisoquine	1 h	<3
Debrisoquine	2,5 h	<2
4-OH-Debrisoquine	1 h	Below detection limit
4-OH-Debrisoquine	2,5 h	Below detection limit
Chlorzoxazone	1 h	>20, overlap; estimated based on SNR
Chlorzoxazone	2,5 h	>20, overlap; estimated based on SNR
6-OH-Chlorzoxazone	1 h	<3
6-OH-Chlorzoxazone	2,5	<3
Plasma		
Caffeine	1 h	5 - 7
Caffeine	2 h	5 - 10
Chlorzoxazone	1 h	Below detection limit
Chlorzoxazone	2 h	Below detection limit

- In order to improve the detection limit, biofluid samples may be concentrated (e. g.
- 10 by freeze-drying) before hyperpolarisation.

Calculation of metabolic ratio:

- The metabolic ratio is being used as a measure of the activity of an individual CYP450 isoenzyme and calculated as the percentage of unchanged probe compounds
- 15 present in the biofluid sample related to the percentage of metabolite. Thus, the calculation of the metabolic ratio of chlorzoxazone and its primary metabolite 6-hydroxy-debrisoquine is used as a measure for the CYP2E1 activity, the metabolic ratio of caffeine and its primary metabolite paraxanthine is used as a measure for the

CYP1A2 activity and the metabolic ratio of debrisoquine and its primary metabolite 4-hydroxy debrisoquine is used as a measure for the CYP2D6 activity.

5 **Example 2**

Determination of the activity of the CYP450 isoenzymes CYP1A2, CYP2D6 and CYP2E1 using single probe compounds

10 The activity of the CYP450 isoenzymes CYP1A2, CYP2D6 and CYP2E1 was determined using the probe compounds as described in Example 1.

2a) Study performance

15 **SPD rat 1**

Compound	Caffeine
Route of administration	intravenous injection
Dosage	51.8 µmol/kg solubilised in 1 ml 10 mM sodium-phosphate buffer pH 7.3, 0.9% NaCl
20 Urine sample collection	A1) before injection B1) 3 h 10 min after injection C1) 6 h 30 min after injection
Blood sample collection	D1) before injection E1) 3 h 10 min after injection

25

SPD rat 2

Compound	Debrisoquine
Route of administration	intraperitoneal injection
Dosage	34.7 µmol/kg solubilised in 1 ml 10 mM sodium-phosphate buffer pH 7.3, 0.9% NaCl
30 Urine sample collection	A2) before injection B2) 3 h after injection C2) 6 h 50 min after injection

SPD rat 3

	Compound	Chlorzoxazone
	Route of administration	intraperitoneal injection
5	Dosage	37.5 µmol/kg solubilised in 240 µl PEG-300
	Urine sample collection	A3) before injection B3) 2 h 45 min after injection C3) 5 h 30 min after injection
	Blood sample collection	E3) before injection F3) 2 h 45 min after injection G3) 5 h 30 min after injection
10		

The volume of urine collected for each period was in the range of 1 to 10 ml for each of the subjects. After collection, blood samples were spun down at 2000 rpm for 10 min. and the plasma was collected. Both, plasma and urine samples, were frozen at – 20 ° C.

2b) Hyperpolarisation of the collected samples and NMR analysis

A stock solution of tritylradical Tris(8-carboxyl-2,2,6,6-tetra(2-(1-hydroxyethyl))-benzo[1,2-d:4,5-d']bis(1,3)dithiole-4-yl)methyl sodium salt (428 mg, 300 µmol) in glycerol (12.61 g) was prepared. Aliquots of the stock solution (51.0 mg) were mixed with 40 µl biofluid (urine or blood plasma) to give a 15 mM trityl radical solution. These solutions were dispensed as droplets into liquid nitrogen to provide the material as vitrified pellets suitable for hyperpolarisation. The solid samples were placed in turn within the DNP magnet and hyperpolarised overnight. The samples were dissolved by injection of a mixture of methanol and acetic acid (100:1). The dissolved samples were quickly transferred manually (approx. 4 s. transfer time) to a high-resolution magnet of 9.4 T and single acquisition ¹³C-1D-NMR-spectra were acquired.

2c) Results

A large number of signals were expected for the probe compounds and their metabolites. In addition the biofluid matrix signals and the solvent signals were also expected to be present in the spectra. For caffeine, major caffeine metabolites were expected to be 1,3-dimethyl uric acid; 1, 3, 7-trimethyl uric acid and paraxanthine. Further minor caffeine metabolites were expected to be 1-xanthine, 1, 3-xanthine; 3, 7-xanthine; 1, 3, 7-DAU; 3, 7-uric acid; 1, 7-uric acid and 1-uric acid. For debrisoquine, several metabolites including 4-hydroxy debrisoquine were present in addition to debrisoquine itself. In the urine sample collected after 3 h, only debrisoquine and 4-hydroxy debrisoquine were present. Additionally, two unknown signals were present which were possibly urine background signals. Expected debrisoquine metabolites are 1-hydroxy debrisoquine, 3-hydroxy debrisoquine, 4-hydroxy debrisoquine 2-(guanidinoethyl)benzoic acid, 2-(guanidinomethyl)phenyl acetic acid and "dihydroxy" debrisoquine.

15

Quantification:

A known amount of each of the unlabelled probe compounds caffeine, chlorzoxazone, debrisoquine and their primary metabolites had been spiked into SPD rat urine samples, hyperpolarisation and NMR analysis was carried out as described above. From these experiments it was possible to estimate an enhancement factor for the carbon atoms of interest in the individual probe compound and its metabolites. Quantification of the unknown amount of probe compound/metabolites in the biofluid samples was based on these enhancements and the known amount of probe compound/metabolite used to generate it. The carbon signal of interest was integrated and this integral value was adjusted (division by 90, 1.1% natural abundance ^{13}C) to account for the unlabelled probe compounds used in the spiked samples compared to the isotopically enriched probe compounds used in the biofluid samples. This integral was then related to the concentration of probe compound used in the spiked samples and compared to the integral obtained for the individual carbon signals identified in the biofluid samples. A careful phase and baseline correction had been performed before integration and the integral window was pre-adjusted to 25 Hz in all measurements. In case of signal overlap an estimated value had been obtained using the signal to noise ratio of the signals of interest.

30

The following concentration ranges were obtained:

Urine	Sample collected after	Concentration range (µg/ml)
Caffeine	3 h	2-4
Paraxanthine	3 h	Below detection limit
unknown caffeine metabolites	3 h	<2-4
Debrisoquine	3 h	7-11
Debrisoquine	6 h	10-20
4-OH-Debrisoquine	3 h	2-4
4-OH-Debrisoquine	6 h	<2
unknown debrisoquine metabolites 1-4, 6 hours	6 h	1-2
Chlorzoxazone	3 h	15-20, overlap estimated based on SNR
Chlorzoxazone	6 h	>50, overlap; estimated based on SNR
6-OH-Chlorzoxazone	3 h	Below detection limit
6-OH-Chlorzoxazone	6 h	Below detection limit
Plasma		
Caffeine	3 h	<4
Chlorzoxazone	3 h	<3

5

In order to improve the detection limit, biofluid samples may be concentrated (e.g. freeze dried) before hyperpolarisation.


Example 3

- 10 **Determination of the activity of the CYP450 isoenzyme CYP3A4 and determination of the activity of the CYP450 isoenzyme CYP3A in the presence of the putative drug diltiazem**

3a) Probe compound

- 15 The activity of the CYP450 isoenzyme CYP3A4 (CYP3A6 in rabbit) was determined using isotopically labelled carbamazepine (CBZ) as a substrate for CYP3A4/CYP3A6. CBZ is through this pathway metabolised to its epoxide (E-CBZ).

Carbamazepine (CBZ)



5

3b) Initial pharmacokinetic study

In order to obtain a pharmacokinetic profile, rabbits ($n=6$) were fed a single dose of 40 mg/kg CBZ (as a sorbitol suspension) in the morning of the first study day. Samples were collected at 8 time points over a period of 24 hours, at the following times: 0 min., 15 min., 30 min., 1 hour, 2 hours, 4 hours, 8 hours and 24 hours. 2 ml blood was withdrawn from the marginal ear vein of the rabbit. Plasma was extracted from the blood and divided into two samples, one for LC-MS analysis and one for DNP analysis (~0.5 ml for each). This study enabled a calculation of the maximum plasma concentration of CBZ over the measured time period (C_{max}), the determination of the time at which the plasma concentration of CBZ is at its maximum (T_{max}) and the half-life of CBZ in plasma ($T_{1/2}$).

20

3c) Inhibition of CBZ by the competitive CYP3A4 substrate diltiazem.

As the drug-drug interaction is a competition for binding, the effect of administering diltiazem together with CBZ is expected to be instantaneous. Diltiazem was prepared as a saline solution of diltiazem hydrochloride. It was given as an intravenous injection twice a day. Once 10 min. prior to the oral administration of CBZ and the second time 4 hours post this administration. The dose of diltiazem was 2 mg/kg/day. The pharmacokinetic study was performed as described in a).

25

The plasma levels of CBZ are expected to increase (~30%) since the Diltiazem itself is a substrate for CYP3A and thus will hinder a full active metabolism of CBZ.

5 **3d) Hyperpolarisation of the collected samples and NMR analysis**

Sample preparation

Rabbit plasma (400 µl) in a 2 ml vial was treated with acetonitrile (750 µl) and sonicated with a sonication probe for 15 sec. Another portion of acetonitrile (750 µl) was added to the vial so as to rinse the probe, the vial was closed, agitated briefly on a whirly mixer and centrifuged at 14 000 rev/min for about 1 min. The supernatant was transferred into a fresh vial in portions and evaporated in a ThermoSavant SPD 111V speedvac. Towards the end of the evaporation, 20 µl of an aqueous stock solution of EDTA (1µg /µl) was added and the mixture was evaporated to dryness. 50 µl of the stock solvent as described below was added to the solid residue, and the added weight was noted. The sample was sonicated for 15 min to dissolve the residue and centrifuged to force the whole sample to the bottom of the vial. The vial was weighed together with a pipette tip and the sample was collected into the pipette tip and dispensed drop wise into liquid nitrogen. The used vial and pipette tip was weighed again to assess the actual weight of the sample. The cooled sample pellets were placed in a sample cup and administered into a DNP-polariser. The sample pellets were polarised for 23 hrs at 93.934 GHz and 100mW in a helium bath (T = 1.1-1.2 K).

Stock solution for preparation of plasma samples

15 1,1-bis(hydroxymethyl)cyclopropane-1-13C-d8 (HP 001), 7.82 mg (70.3 µmol) was dissolved in 10.00 g (0.161 mol) glycol. A 500 mg aliquot of this solution was diluted to 5000 mg (4.492 ml) with glycol and tris(8-carboxyl-2,2,6,6-tetra(2-(1-hydroxyethyl))-benzo[1,2-d:4,5-d']bis(1,3)dithiole-4-yl)methyl sodium (OX 063), 96.14 mg (67.4 µmol), was added to the mixture. A 50 µl (55.6 mg) aliquot of this solution contains 4.35 µg HP 001 and is 15 mM with respect to OX 063. The volume of the radical is not accounted for in the calculation.

Sample dissolution after hyperpolarisation

The sample was dissolved in heated (60 °C) methanol-D₄ containing 75 µg EDTA per 7.0 ml of methanol. The dissolved sample was collected in a 10 mm NMR-tube fitted with a NMR-spinner and kept in a portable magnetic field (12 mT). The
5 sample was moved from the polariser into the NMR magnet as expediently as possible making sure that the tube is protected in the portable magnetic field during the transport.

NMR analysis

10 A 1D ¹³C NMR-spectrum was acquired with a 10 mm Varian direct detection probe at 100.393 MHz (400 MHz ¹H). The 10 mm test tube had an active volume of 0.9 ml. The NMR acquisition parameters were a spectral width of 40 kHz (400 ppm), an acquisition time of 2.5 s, and a pulse angle of 90. All NMR spectra were referenced relative to glycol in methanol at 64.482 ppm. The spectrum was acquired 5 s after
15 dissolution was initiated.

3e) Quantification

Quantification of the NMR signals was carried out using jMRUI, a software package to analyze the NMR signals in the time domain (MAGMA 2001 May; 12(2-3), 141-
20 152). First, the reference ¹³C-NMR signal from HP001 was analysed by selecting one Lorentzian line shape model function to describe the signal. The algorithm calculates phase, amplitude, damping (or line width in frequency domain) and frequency. The first order phase was set fixed at zero. Second, the ¹³C-NMR signals from CBZ and its epoxide metabolite (E-CBZ) are analysed. All phases of the peaks
25 were zero with respect to the main phase and a Lorentzian line shape model function was assumed. For the ¹³C-NMR resonances of CBZ and E-CBZ equal line widths and a frequency separation of 90.3537 ppm are used. This prior knowledge was derived from the DNP-NMR spectra of the two components in the solvent and at the temperature used and improved the robustness of the quantification method of
30 especially E-CBZ at the lower signal-to-noise ratio (SNR). The first order phase was fixed at zero, the zero order phase was determined by the algorithm. The amplitudes calculated for CBZ and E-CBZ were divided by the amplitude found for the

reference compound HP001 and give a relative intensity for the parent compound CBZ and its primary metabolite E-CBZ.

3f) Results

- 5 A calibration curve was made at 6 concentration levels using ^{13}C -labelled CBZ. 0.11 μg , 0.33 μg , 0.5 μg , 1.0 μg , 1.5 μg , and 2.0 μg were spiked into 400 μl rabbit plasma, incubated at 37 °C and prepared as described in the section on sample preparation.
- 10 The pharmaco-kinetics of CBZ was determined by analysing the NMR spectra of the hyperpolarised plasma samples. The level of CBZ increased when diltiazem was co-administered due to the inhibition of carbamazepine metabolism. This increase was easily seen in the NMR spectra. The increase detected by the method according to the invention was fully in line with what was measured by LC-MS. Also an inter-
- 15 rabbit comparison on three rabbits showed the two techniques to perform comparably.

Based on the analysis performed using DNP-NMR and LC-MS, respectively commonly used pharmaco-kinetic parameters were extracted, see tables 1 and 2.

20

Table 1

Analytical method	C_{max} (μM)	$\text{AUC}_{0-5\text{sh}}$ ($\mu\text{M hour}$)
LC-MS (CBZ)	13.30	60
DNP-NMR (CBZ)	12.00	52
LC-MS (CBZ+ diltiazem)	15.08	87
DNP-NMR (CBZ+ diltiazem)	13.70	75

CBZ levels calculated. AUC means area under the curve in a measured time period.

- 25 Values are presented for LC-MS and DNP-NMR for CBZ alone and in combination with diltiazem.

Table 2

Analytical method	C _{max} (μM)	AUC _{0.5-8h} (μM hour)
LC-MS (CBZ)	13.30	60
DNP-NMR (CBZ)	12.00	52
LC-MS (CBZ+diltiazem)	15.08	87
DNP-NMR (CBZ+ diltiazem)	13.70	75

5

E-CBZ levels calculated. AUC means area under the curve in a measured time period. Values are presented for LC-MS and DNP-NMR for CBZ alone and in combination with diltiazem.

10

Claims

1. Method for determining *in vivo* protein activity comprising
- 5 a) hyperpolarising the NMR active nuclei of samples collected from a human or non-human animate body preadministered with at least one probe compound containing at least one NMR active nuclei and
- b) analysing said samples by NMR spectroscopy
- 10 2. Method according to claim 1 wherein from said analysis of step b) an NMR pattern I is generated, the method comprises the further steps of
- c) hyperpolarising the NMR active nuclei of samples collected from a human or non-human animate body preadministered with said at least one probe compound and at least one putative drug,
- 15 d) analysing said samples by NMR spectroscopy and hereby generating an NMR pattern II,
- e) comparing the NMR patterns I and II thus identifying distinctions in the NMR pattern II, which are due to the administration of the putative drug.
- 20 3. Method according to claims 1 to 2 wherein at least two probe compounds are selected.
4. Method according to claims 1 to 3 wherein the probe compounds are enriched with NMR active nuclei.
- 25 5. Method according to claims 1 to 4 wherein hyperpolarisation is carried out by means of polarisation transfer from a noble gas, brute force, dynamic nuclear polarisation (DNP) or spin refrigeration.
- 30 6. Method according to claims 1 to 5 wherein the collected samples are biofluids.
7. Method according to claims 1 to 6 wherein said probe compounds are substrates, inducers or inhibitors for Cytochrome P 450 (CYP450)

8. Method according to claim 7 wherein said probe compounds are substrates, inducers or inhibitors for CYP 450 isoenzymes selected from the group consisting of CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.
9. Method according to claims 1 to 8 for phenotyping
10. Method according to claims 2 to 8 for studying drug-drug interaction.
11. Mixture comprising at least two probe compounds, all probe compounds being enriched with ^{13}C - and/or ^{15}N NMR active nuclei.
12. Mixture according to claim 11 wherein said mixture comprises at least 3 probe compounds, preferably at least 4 probe compounds.
13. Mixture according to claims 11 to 12 wherein said probe compounds are probe compounds that interact with proteins selected from the group consisting of NADPH quinone oxidoreductases, CYP450, N-acetyltransferase, glutathione transferase, thiomethyltransferase, thiopurine methyltransferase, sulfotransferase, UDP-glucuronosyl transferase, pseudocholinesterase, serotonin transport protein, ATP binding cassette (ABC's) and p-glycoprotein.
14. Mixture according to claims 11 to 13 wherein the mixture comprises probe compounds selected from the group consisting of phenacetin, coumarin, tolbutamide, phenytoin, mephenytoin, S-mephenytoin, bufuralol, chlorzoxazone, midazolam, caffeine, dapsone, diclofenac, debrisoquine, bupropion, antipyrine, dextromethorphan, warfarin, diazepam, alprazolam, triazolam, flurazepam, chlordiazepoxide, theophylline, phenobarbital, propranolol, metoprolol, labetalol, nifedipine, digitoxin, quinidine, mexiletine, lidocaine, imipramine, flurbiprofen, omeprazole, terfenadine, furafylline, codeine, nicotine, sparteine, erythromycin, benzoylcholine, butyrylcholine, paraoxon, para-aminosalicylic acid, isoniazid, sulfamethazine, 5-fluorouracil, trans-stilbene oxide, D-penicillamine, captopril, ipomeanol, cyclophosphamide, halothane, zidovudine, testosterone,

acetaminophen, hexobarbital, carbamazepine, cortisol, oltipraz, cyclosporin A and paclitaxel.

15. Mixture according to claims 11 to 13 wherein the mixture comprises probe compounds selected from the group consisting of sulfathiazole, dapsone, isoniazid, sulfamethoxazole, hydrazaline, caffeine and procainamide.
16. Mixture according to claims 11 to 13 wherein the mixture comprises probe compounds selected from the group consisting of phenobarbital, oltipraz and 3-methyl-cholanthrene.
17. Mixture according to claims 11 to 13 wherein the mixture comprises probe compounds selected from the group consisting of azathioprine, mercaptopurine and thioguanine.
18. Mixture according to claims 11 to 17 wherein the mixture further comprises at least one putative drug.
19. Use of the mixture according to claims 11 to 17 for the determination of *in vivo* protein activity, preferably for phenotyping.
20. Use of the mixture according to claim 18 for studying drug-drug interaction.
21. Mixture comprising at least two probe compounds, all probe compounds being enriched with ^{13}C and/or ^{15}N NMR active nuclei, for use as an agent for determining *in vivo* protein activity.
22. Mixture comprising at least two probe compounds, all probe compounds being enriched with ^{13}C and/or ^{15}N NMR active nuclei, for the manufacture of an agent for determining *in vivo* protein activity.
23. Mixture according to claims 21 to 22 wherein the mixture further comprises at least one putative drug.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/NO 03/00125

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/00 G01R33/465 G01N24/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q G01R G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01 96895 A (COOK NEIL ;LOOKER MIKE (GB); BOSWORTH NIGEL (GB); KNOX PETER (GB); 20 December 2001 (2001-12-20) abstract; claims 1-17	1-23
Y	WO 00 40988 A (COOK NEIL ;KNOX PETER (GB); NYCOMED AMERSHAM PLC (GB); AXELSSON OK) 13 July 2000 (2000-07-13) abstract page 15, line 19 -page 16, line 10	1-23

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

19 August 2003

Date of mailing of the international search report

- 5. 09. 2003

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Malin Söderman

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/NO 03/00125

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AKIRA K ET AL: "Direct nuclear magnetic resonance spectroscopic analysis of (13)C-labeled antipyrine metabolites in human urine." DRUG METABOLISM AND DISPOSITION: THE BIOLOGICAL FATE OF CHEMICALS. UNITED STATES JUN 2001, vol. 29, no. 6, June 2001 (2001-06), pages 903-907, XP002251641 ISSN: 0090-9556 abstract page 903	1-23
A	--- SCOTT R J ET AL: "Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry." RAPID COMMUNICATIONS IN MASS SPECTROMETRY: RCM. ENGLAND 1999, vol. 13, no. 23, 1999, pages 2305-2319, XP002251642 ISSN: 0951-4198 abstract page 2305, column 2, line 11 -page 2306, column 1, line 8	1-23
A	--- STEVENS J C ET AL: "Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis." THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. UNITED STATES AUG 1999, vol. 290, no. 2, August 1999 (1999-08), pages 594-602, XP002251643 ISSN: 0022-3565 abstract	1-23

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NO 03/00125

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KOUDRIAKOVA T ET AL: "In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats." THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. UNITED STATES DEC 1996, [Online] vol. 279, no. 3, December 1996 (1996-12), pages 1300-1309, XP002251644 ISSN: 0022-3565 Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/gyery.fcgi?cmd=Retrieve&db=PubMed&list_uid..> [retrieved on 2003-08-15] abstract</p> <p>-----</p>	1-23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NO 03/00125

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-10
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 1-10

Claims 1-10 relate to a method of treatment of the human or animal body by surgery or by therapy/ a diagnostic method practised on the human or animal body/Rule. 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NO 03/00125

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0196895	A	20-12-2001	AU	6407201 A		24-12-2001
			EP	1290461 A1		12-03-2003
			WO	0196895 A1		20-12-2001
WO 0040988	A	13-07-2000	AU	1880300 A		24-07-2000
			CA	2356442 A1		13-07-2000
			EP	1141738 A1		10-10-2001
			WO	0040988 A1		13-07-2000
			JP	2002534687 T		15-10-2002